Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report? [Yahoo! Finance]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Yahoo! Finance
Will the recent negative trend continue leading up to its next earnings release, or is Beam Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. Beam Therapeutics Q2 Earnings Beat, Revenues Miss Beam Therapeutics incurred a loss of $1.11 per share in the second quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of $1.13. The company had recorded a loss of $1.08 per share in the year-ago quarter. Total revenues, comprising license and collaboration revenues, came in at $11.7 million in the second quarter compared with $20.1 million reported in the year-ago period. The top line missed the Zacks Consensus Estimate of $14 million. Quarter in Detail Research and development expenses were $87 million in the second quarter, down almost 10.8% from the year-ago quarter's level. General and admini
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at Stifel Nicolaus from $66.00 to $69.00. They now have a "buy" rating on the stock.MarketBeat
- Glycogen Storage Disease Type 1a (GSD-1a) Treatment and Market Landscape Report 2024 [Yahoo! Finance]Yahoo! Finance
- Lipid Nanoparticles Market to Reach $3.1 Billion, Globally, by 2033 at 13.1% CAGR: Allied Market Research [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.MarketBeat
- Beam Therapeutics Inc. (NASDAQ: BEAM) had its price target raised by analysts at JPMorgan Chase & Co. from $45.00 to $48.00. They now have an "overweight" rating on the stock.MarketBeat
BEAM
Earnings
- 5/7/24 - Beat
BEAM
Sec Filings
- 9/3/24 - Form 4
- 8/19/24 - Form 3
- 8/6/24 - Form 10-Q
- BEAM's page on the SEC website